Literature DB >> 15557141

Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells.

Samuel Huber1, Christoph Schramm, Hans A Lehr, Amrit Mann, Steffen Schmitt, Christoph Becker, Martina Protschka, Peter R Galle, Markus F Neurath, Manfred Blessing.   

Abstract

Data regarding the role of TGF-beta for the in vivo function of regulatory CD4(+)CD25(+) T cells (Treg) are controversial. A transgenic mouse model with impaired TGF-beta signaling specifically in T cells was used to assess the role of endogenous TGF-beta for the in vivo function of CD4(+)CD25(+) Treg in a murine model of colitis induced by dextran sulfate. Transfer of wild-type, but not transgenic CD4(+)CD25(+) Treg was found to suppress colitis in wild-type mice. In addition, by transferring CFSE-labeled CD4(+)CD25(+) Treg we could demonstrate that endogenous TGF-beta promotes the expansion of CD4(+)CD25(+) Treg in vivo. Transgenic mice themselves developed reduced numbers of peripheral CD4(+)CD25(+) Treg and were more susceptible to the induction of colitis, which could be prevented by the transfer of wild-type Treg. These data indicate that TGF-beta signaling in CD4(+)CD25(+) Treg is required for their in vivo expansion and suppressive capacity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557141     DOI: 10.4049/jimmunol.173.11.6526

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  100 in total

1.  Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells.

Authors:  Shuai Tang; Miranda L Moore; Jason M Grayson; Purnima Dubey
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

Review 2.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

3.  Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.

Authors:  Luke S Manlove; Katherine E Berquam-Vrieze; Kristen E Pauken; Richard T Williams; Marc K Jenkins; Michael A Farrar
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

4.  Dysfunctional T regulatory cells in multiple myeloma.

Authors:  Rao H Prabhala; Paola Neri; Jooeun E Bae; Pierfrancesco Tassone; Masood A Shammas; Charles K Allam; John F Daley; Dharminder Chauhan; Elizabeth Blanchard; Hemant S Thatte; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  Increase of CD4(+)CD25(+) T cells in Smad3(-/-) mice.

Authors:  Zi-Bing Wang; Yu-Fang Cui; Yu-Qing Liu; Wei Jin; Han Xu; Zhu-Jun Jiang; Ya-Xin Lu; Ying Zhang; Xiao-Lan Liu; Bo Dong
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

6.  Oral tolerance in the absence of naturally occurring Tregs.

Authors:  Daniel Mucida; Nino Kutchukhidze; Agustin Erazo; Momtchilo Russo; Juan J Lafaille; Maria A Curotto de Lafaille
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

Review 7.  Regulatory T cells: present facts and future hopes.

Authors:  Christian Becker; Sabine Stoll; Tobias Bopp; Edgar Schmitt; Helmut Jonuleit
Journal:  Med Microbiol Immunol       Date:  2006-05-20       Impact factor: 3.402

Review 8.  Regulatory T cells in pregnancy.

Authors:  Ana Claudia Zenclussen
Journal:  Springer Semin Immunopathol       Date:  2006-07-13

Review 9.  Novel developments in the mechanisms of immune tolerance to allergens.

Authors:  Thomas Eiwegger; Saskia Gruber; Zsolt Szépfalusi; Cezmi A Akdis
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

10.  The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease.

Authors:  K Kamikozuru; K Fukunaga; S Hirota; N Hida; Y Ohda; K Yoshida; Y Yokoyama; K Tozawa; K Kawa; M Iimuro; K Nagase; A R Saniabadi; S Nakamura; H Miwa; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.